Albuminar-25 Market Report 2026

Albuminar-25 Market Overview

• The Albuminar-25 market growth in the historic period has been driven by use of concentrated albumin in shock, established surgical protocols • Market expansion is supported by rising critical care admissions, increasing liver disease burden • Growth Driver: The Demand For Biopharmaceuticals Fuel The Growth Of Albuminar-25 Market • North America was the largest region in 2025.

What Is Covered Under Albuminar-25 Market?

Albuminar-25 is a pharmaceutical preparation of albumin, a protein derived from human plasma. It is primarily used in medical settings for various therapeutic purposes. It is derived from pooled human plasma and helps maintain oncotic pressure, aiding in fluid balance and circulation. The main formulations of albuminar-25 are human serum albumin, recombinant albumin, and bovine serum albumin. Human serum albumin (HSA) is a protein found in blood plasma that plays a critical role in maintaining the osmotic pressure of blood, which helps regulate fluid balance within the body. The various indications include shock treatment, burns, and hypoalbuminemia and are used by various end-users such as hospitals and clinics, the pharmaceutical & biotechnology industry, and research institutes.

What Is The Albuminar-25 Market Growth Forecast?

The growth in the forecast period can be attributed to rising critical care admissions, increasing liver disease burden, expansion of surgical procedures, stable plasma supply chains, hospital demand for concentrated therapies. Major trends in the forecast period include use of high concentration albumin solutions, preference in critical fluid management, adoption in surgical and ICU settings, steady demand in hypoalbuminemia, clinical reliance on plasma proteins.

Global Albuminar-25 Market Segmentation

1) By Formulation: Human Serum Albumin, Recombinant Albumin, Bovine Serum Albumin 2) By Indication: Shock Treatment, Burns, Hypoalbuminemia 3) By End User: Hospitals And Clinics, Pharmaceutical & Biotechnology Industry, Research Institutes

What Are The Drivers Of The Albuminar-25 Market?

The increasing demand for biopharmaceuticals is expected to propel the growth of the albuminar-25 market going forward. Biopharmaceuticals are therapeutic products derived from biological sources produced using living organisms, such as bacteria, yeast, mammalian cells, or plants, through advanced biotechnology methods. The rising demand for biopharmaceuticals is due to the growing prevalence of chronic diseases, advancements in treatments, and the increasing use of albumin in drug formulations and clinical therapies. Albumin’s crucial role in drug delivery systems and its ability to stabilize therapeutic proteins makes it an indispensable component in the development of biopharmaceuticals, further fueling the growth of the albumin market within the pharmaceutical industry. For instance, in October 2025, according to the Gov.UK, a UK-based government agency, companies operating in the biopharmaceutical subsector generated $129.64 billion (£98.9 billion) in turnover in 2023/2024, which accounted for 67% of the life sciences industry total. Therefore, the increasing demand for biopharmaceuticals drives the albuminar-25 industry. Rising demand for personalized medicine is expected to propel the growth of the albuminar-25 market going forward. Personalized medicine is a medical approach that tailors treatment and healthcare strategies to the individual characteristics of each patient, such as their genetic makeup, environment, and lifestyle, to achieve the most effective and precise outcomes. The rising personalized medicine is due to advancements in genomic technologies, increased understanding of molecular biology, growing availability of precision diagnostic tools, and the demand for targeted therapies that improve patient outcomes while minimizing side effects. Albuminar-25, a human serum albumin product, plays a crucial role in personalized medicine by serving as a reliable plasma protein replacement in patients with specific therapeutic needs, particularly in maintaining fluid balance, supporting drug delivery, and modulating the body's immune response, thus enhancing the efficacy of individualized treatments for conditions such as burns, trauma, and liver disease. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, a significant increase from the six approved in 2022. Therefore, rising personalized medicine drives the albuminar-25 industry. The rise in healthcare spending is expected to propel the growth of the albuminar-25 market going forward. Healthcare spending refers to the financial resources individuals, governments, private insurers, and other entities allocate to provide healthcare services and products. The rise in healthcare spending is attributed to an aging population, medical technology advancements, chronic disease prevalence, and increased demand for healthcare services. Healthcare spending plays a crucial role in supporting the availability and accessibility of Albuminar-25, as it allows for increased investment in life-saving treatments, enabling hospitals and clinics to purchase and stock essential intravenous albumin solutions for patients requiring critical care for conditions like shock and severe protein deficiencies. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, between 2022 and 2023, healthcare spending in the UK increased by 5.6% compared with growth of 0.9% in 2022. The UK healthcare expenditure in UK healthcare expenditure was around $317.63 billion (£292 billion) in 2023. Therefore, the rise in healthcare spending is driving the growth of the albuminar-25 industry

Key Players In The Global Albuminar-25 Market

Major companies operating in the albuminar-25 market are Grifols S.A.

Regional Insights

North America was the largest region in the albuminar-25 market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Albuminar-25 Market?

The albuminar-25 market consists of sales of sodium caprylate and sodium acetyltryptophanate. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Albuminar-25 Market Report 2026?

The albuminar-25 market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the albuminar-25 industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.